Scientists identify a hidden protein interaction that drives Parkinson's
Researchers found that alpha-synuclein hijacks a mitochondrial enzyme — and built a decoy compound, CS2, that blocks the harmful interaction.
A team at Case Western Reserve University has uncovered a molecular interaction that helps accelerate Parkinson's by sabotaging the brain's energy supply. Writing in Molecular Neurodegeneration, the researchers showed that alpha-synuclein — the protein that clumps abnormally in Parkinson's — binds to a mitochondrial enzyme called ClpP, disrupting how brain cells generate energy.
To counter it, the team designed a compound named CS2 that acts as a decoy, intercepting the harmful interaction before it can damage mitochondria. In experimental models, including human brain tissue and mice, CS2 reduced inflammation and led to improvements in both movement and cognitive performance.
Crucially, the approach targets a root mechanism of the disease rather than simply easing symptoms. The researchers anticipate that clinical trials could follow within about five years.
This is an in-house summary. Read the full reporting at the original source:
